Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 6/20 | 0.60 |
| ▸ | GRIN2B | Q13224 | 8/20 | 0.57 |
| ▸ | JAK2 | O60674 | 7/20 | 0.57 |
| ▸ | JAK3 | P52333 | 7/20 | 0.57 |
| ▸ | TYK2 | P29597 | 5/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.56 |
| ▸ | HPGDS | O60760 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.55 |
| ▸ | NSD2 | O96028 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20183411 | 1.00 | JAK1 (0.60) | JAK1GRIN2BJAK2JAK3TYK2 | |
| SCHEMBL661442 | 0.82 | ROCK2 (0.61) | JAK1JAK2JAK3TYK2 | |
| SCHEMBL12346535 | 0.82 | ROCK2 (0.61) | JAK1JAK2JAK3TYK2 | |
| SCHEMBL23619474 | 0.82 | JAK3 (0.56) | JAK1JAK2JAK3TYK2HPGDS | |
| SCHEMBL3537589 | 0.80 | CYP1A2 (0.63) | JAK1JAK2JAK3TYK2CYP2D6 | |
| SCHEMBL1120768 | 0.79 | JAK2 (0.62) | JAK1JAK2JAK3TYK2CYP2D6 | |
| SCHEMBL1376865 | 0.79 | JAK2 (0.62) | JAK1JAK2JAK3TYK2CYP2D6 | |
| SCHEMBL20708022 | 0.78 | GRIN2B (0.84) | GRIN2BCYP2D6KCNH2 | |
| SCHEMBL23339201 | 0.78 | HPGDS (0.65) | JAK1GRIN2BJAK3CYP2D6HPGDS | |
| SCHEMBL4315728 | 0.77 | HTT (0.64) | GRIN2BHTTSMN1; SMN2CYP2D6HPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108137608-B | Janus kinase 1 selective inhibitor and pharmaceutical application thereof | 阳智化学（株） | 2020-06-19 | — | — | CN | disclosed |
| US-10407430-B2 | Janus kinase 1 selective inhibitor and pharmaceutical use thereof | YANG JI CHEMICAL CO., LTD. (KR) | 2019-09-10 | — | — | US | disclosed |
| US-20180237440-A1 | JANUS KINASE 1 SELECTIVE INHIBITOR AND PHARMACEUTICAL USE THEREOF | YANG JI CHEMICAL CO., LTD. (KR) | 2018-08-23 | — | — | US | disclosed |
| EP-3327021-A1 | JANUS KINASE 1 SELECTIVE INHIBITOR AND PHARMACEUTICAL USE THEREOF | Yangji Chemical Co., Ltd. (KR) | 2018-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10407430-B2 | Janus kinase 1 selective inhibitor and pharmaceutical use thereof | JAK1, JAK2, JAK3 | JAK1 1/4885GRIN2B 1171/4885JAK2 2/4885 |
| US-20180237440-A1 | JANUS KINASE 1 SELECTIVE INHIBITOR AND PHARMACEUTICAL USE THEREOF | JAK1, JAK2, JAK3 | JAK1 1/4885GRIN2B 1129/4885JAK2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.